Status:
TERMINATED
A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva and gemcitabine, and of gemcitabine monotherapy, as first line treatment of elderly patients, or patients wit...
Eligibility Criteria
Inclusion
- adult patients, \>=70 years of age or with ECOG PS of 2;
- advanced (stage IIIB or IV)non-small cell lung cancer;
- no prior systemic chemotherapy for advanced NSCLC or prior treatment with HER-axis targeted drugs.
Exclusion
- active brain metastasis or spinal cord suppression;
- unstable systemic disease.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT00940875
Start Date
June 1 2009
End Date
September 1 2011
Last Update
April 2 2015
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Port Macquarie, New South Wales, Australia, 2444
2
Randwick, New South Wales, Australia, 2031
3
Sydney, New South Wales, Australia, 2139
4
Sydney, New South Wales, Australia, 2747